Assess the Influence of Nicotine Flux and Nicotine Form on Subjective Effects Related to Dependency
Launched by AMERICAN UNIVERSITY OF BEIRUT MEDICAL CENTER · Jun 20, 2022
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying how different ways of delivering nicotine through electronic nicotine delivery systems (ENDS), like vaping devices, affect feelings of addiction and dependency. Researchers want to understand how the amount of nicotine released (called "nicotine flux") and the form it takes impact users' cravings and urges to use nicotine. This information is important because it could help create better regulations to reduce nicotine addiction, especially among young people who are increasingly using these devices.
To participate in this trial, you need to be at least 18 years old and a healthy adult who currently uses ENDS or cigarettes regularly. Participants will need to stop using nicotine for at least 12 hours before joining the study. During the trial, you will use different ENDS devices that release varying amounts of nicotine, and researchers will assess how this affects your cravings and feelings of dependency. It's essential to note that individuals with certain health conditions or those planning to quit tobacco in the near future may not be eligible for this study. Overall, this research aims to gather crucial evidence to help shape effective public health policies around nicotine delivery and addiction.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Must be healthy and above 18 years of age
- • Must be willing to provide informed consent, attend the lab, and abstain from tobacco/nicotine as required (participants will be instructed to abstain from nicotine/tobacco and/or ENDS use for ≥12h)
- • A dual ENDS and tobacco user who reports daily use of ENDS (≥ 3 mg/ml nicotine) or cigarettes (any frequency) AND someday use (≥ 3 days/week) of ENDS (≥ 3 mg/ml nicotine) or cigarettes (any frequency) for the past 3 months or longer
- Exclusion Criteria:
- • History of chronic disease or an uncontrolled psychiatric condition
- • History of or active cardiovascular disease, low/high blood pressure, seizures, regular use of a prescription medication (except vitamins/birth control)
- • Past month use of cocaine, opioids, benzodiazepines, or methamphetamines
- • Individuals who report using marijuana \>15/30 days
- • Women will be excluded if they are breast-feeding or pregnant
- • Participants intending to quit tobacco/nicotine use in the next 30 days and referred to cessation treatment
About American University Of Beirut Medical Center
The American University of Beirut Medical Center (AUBMC) is a leading academic medical institution in the Middle East, dedicated to advancing healthcare through innovative research, education, and clinical excellence. As a prominent sponsor of clinical trials, AUBMC integrates cutting-edge scientific inquiry with patient-centered care to enhance therapeutic options and improve health outcomes. With a commitment to ethical standards and regulatory compliance, AUBMC collaborates with multidisciplinary teams to conduct rigorous trials that contribute to the global medical knowledge base and address critical health challenges in the region and beyond.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Beirut, , Lebanon
Patients applied
Trial Officials
Soha Talih, PhD
Principal Investigator
American University of Beirut Medical Center
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials